Understanding Revlimid® (lenalidomide)

Revlimid® (lenalidomide) is an oral medication in a class of drugs called immunomodulatory agents. It was first approved by the U.S. Food and Drug Administration (FDA) for patients with myeloma in 2006. Since then, the FDA has approved numerous combination therapies with Revlimid for treatment strategies throughout the myeloma disease course, including as maintenance therapy after autologous stem cell transplant (ASCT). Revlimid is one of the most frequently used medications in myeloma.



Updated February 17, 2023

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.